Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC - RESEARCH TRIANGLE PARK,...
Press release content from Business Wire. The AP news staff was not involved in its creation. Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 April 6, 2021 GMT WHIPPANY, N.J.--(BUSINESS WIRE)--Apr 6, 2021-- Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on th...
ó stata avanzado; presentaciones orales para destacar los resultados de los estudios de fase 3 ACIS, TITAN y SPARTAN SOLO PARA MEDIOS DE COMUNICACIÓN MÉDICOS Y COMERCIALES FARMACÉUTICOS DE LA REGIÓN DE EMEA NO SE PERMITE LA DISTRIBUCIÓN EN EL BENELUX NI EN EL REINO UNIDO Janssen Pharmaceutical Companies de Johnson & Johnson ha anunciado hoy que destacará la solidez de su cartera de tumores sólidos en el Simposio sobre Cánceres Genitourinarios de la Sociedad Americana de Oncología Clínica (American Society of Clinical Oncology Genitourinary, ASCO GU) con 12 presentaciones de datos,...
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results News provided by Share this article Share this article RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposiu...
Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology Published 01 February 2021 I have previously discussed the use of antibody-drug conjugates for selective tumor cell intensification of urothelial carcinoma therapy in a Urotoday Clinical Trials Portal article. 1 Similarly, I’ve also focused on enfortumab vedotin before, and enfortumab vedotin is now FDA approved on the accelerated pathway for patients with locally advanced or metastatic urothelial carcinoma in the post-platinum chemotherapy and post-PD-(L1) antibody therapy setting. 2 ...